Clinical trials: Dry Macular Degeneration
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Geographic Atrophy
Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
This study will seek to enroll 50 persons who have central or non-central geographic atrophy (GA) associated with age-related macular degeneration (AMD). GA in treated eye must be between 0.75 disk areas (DA) and 8 DA.
- Trial name
- Sirolimus (NCT01675947)
- Testing
- Sirolimus, Lidocaine
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration (AMD)
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues.
- Trial name
- NCT02445313
- Testing
- Nidek MP-3
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Doheny Image Reading Center
Age-Related Macular Degeneration
Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study
This study is a prospective, single centre, randomized, sham-controlled, double-masked, clinical trial which aims to investigate the effect of subthreshold nanosecond laser on disease progression in eyes with intermediate…
- Trial name
- LIANA (NCT05200624)
- Testing
- 2RT subthreshold nanosecond laser
- Where
- 4 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Center for Eye Research Australia
Dry AMD, Geographic Atrophy
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Trial name
- VIRETTA (NCT07433088)
- Testing
- Object recognition and selection task
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Streetlab
Geographic Atrophy, Macular Degeneration
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04435366
- Testing
- Avacincaptad Pegol
- Where
- 205 sites in United States, Argentina and 18 more
- Volunteers
- 448 people
- Sponsor
- IVERIC bio, Inc.
Geographic Atrophy (GA)
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to…
- Trial name
- VIENNA (NCT07230834)
- Testing
- Pozelimab
- Where
- 9 sites in United States, Georgia and 2 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Stargardts, Retinitis Pigmentosa
High Resolution Retinal Imaging
Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease.
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia
- Trial name
- AOSLO (NCT01866371)
- Testing
- Retinal imaging
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Geographic Atrophy
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96…
- Trial name
- NCT02745119
- Testing
- Lampalizumab
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 994 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration
Hypothesis: external electrical stimulation of the retina with low level electrical currents improves visual acuity in subjects with age-related dry macular degeneration.
- Trial name
- NCT01600300
- Testing
- Tesmac
- Volunteers
- 40 people
- Sponsor
- Acuity Medical International, Inc.
Geographic Atrophy
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in…
- Trial name
- NCT02288559
- Testing
- Lampalizumab
- Where
- 36 sites in United States
- Volunteers
- 96 people
- Sponsor
- Genentech, Inc.
Dry Age Related Macular Degeneration
Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial
Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative.
- Trial name
- ART (NCT00751361)
- Testing
- Rheopheresis / double filtration plasmapheresis
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Apheresis Research Institute
Dry AMD, Stargardt Disease 1
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.
- Trial name
- MADEOS (NCT03297515)
- Testing
- Madeos
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Ophthalmos Research and Education Institute
Retinitis Pigmentosa, Stargardt Macular Dystrophy
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration
- Trial name
- DEFINE-IRD (NCT07502664)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ray Therapeutics, Inc.
Age-Related Macular Degeneration, Lens, Intraocular
Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss.
- Conditions
- Age-Related Macular Degeneration, Lens, Intraocular, Myopic Maculopathy
- Trial name
- NCT03882606
- Testing
- Scharioth Macula Lens (SML, Medicontur)
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Consorci Sanitari de Terrassa
Dry Age Related Macular Degeneration
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a…
- Trial name
- NCT00541333
- Testing
- Copaxone Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The New York Eye & Ear Infirmary
Geographic Atrophy, Dry Age Related Macular Degeneration
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
- Trial name
- NCT00429936
- Testing
- Fenretinide
- Volunteers
- 245 people
- Sponsor
- Sirion Therapeutics, Inc.
Macular Degeneration, Age Related
Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients
The best treatment to prevent the evolution of early and intermediate forms of dAMD to atrophic degeneration is PhotoBioModulation (PBM).
- Trial name
- PBM-dAMD (NCT06582511)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Francesco Bandello
Geographic Atrophy, Wet Macular Degeneration
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
To investigate pathomorphological and functional variations of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Chinese population using optical coherence tomography (OCT) to find which kinds of…
- Conditions
- Geographic Atrophy, Wet Macular Degeneration, Retinal Drusen
- Trial name
- NCT01666821
- Testing
- Follow-up observation
- Where
- China
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine